Turmeric extract for the prevention of MI

Not Applicable

• Conditions: CAD.; Chronic ischaemic heart disease

• Registration Number: IRCT2013081114330N1
• Lead Sponsor: Mashhad University of Medical Sciences,vice chancellor for research

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 22 February 2018

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 64

Inclusion Criteria

The inclusion criteria: diagnosis of CAD; age above 18-75 years old; giving informed consent. Exclusion criteria: diabetes (assessed by measuring 126 <FBS); renal failure (with BUN, Cr); liver failure (evaluation of liver enzymes ALT, AST and bilirubin); drugs inhibit the immune system; taking pentoxifylline; taking cilostazol; an underlying infectious or inflammatory diseases (based on history and physical examination); having a history of sensitivity to curcumin (turmeric); high CRP (CRP) and Schiff Lvkvstvz the right (at least two positive CRP test qualitative biochemistry and CBC); taking glucosamine (due to inhibitory effects on the inflammatory NF?B); Egypt barberry extract, berberine (due to inhibitory effects on the inflammatory NF?B) and having a history of abuse syndromes induced absorption (based on history).

Exclusion Criteria

Not provided

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Effect of curcumin on the expression of cellular markers of inflammation (NF?B). Timepoint: Before and after study. Method of measurement: Gene expression and proteomics.

Secondary Outcome Measures

Name	Time	Method
Plaque instability indirect parameters such as MMP9, CD40 concentration, and etc. Timepoint: Before the study and after stud. Method of measurement: Measurement of CD40L.